DCE-MRI Evaluation of Eribulin Mesylate in MX-1 Triple Negative Human Breast Cancer Mouse Xenograft Model

Denise C. Welsh¹, Tyler Teceno¹, Ken Ito¹, Mamuro Yanagimachi¹, Deirdre Scully², Jacob Hesterman², Yasuhiro Funahashi¹, Paul J. McCracken¹

The effects of eribulin, a microtubule binding drug approved third line therapy for breast cancer, on the vasculature and tumor growth of human breast cancer mouse MX-1 tumors are compared to capecitabine, a cytotoxic. These DCE-MRI data show evidence of antivascular activity at early time points after eribulin treatment and a stabilization of tumor volume. In addition to stabilizing tumor growth over a 5 day period, we demonstrated that a single dose of 3mg/kg i.v. eribulin reduces tumor Ktrans as early as 6hrs followed by a significant increase in Ktrans by days 2 and 5.